Cytosorbents annual gross margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Cytosorbents's gross margin was 71.48% for fiscal 2025.
View full Cytosorbents company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 71.48% | +1.56 pp |
| 2024 | 2024-12-31 | 69.92% | −0.71 pp |
| 2023 | 2023-12-31 | 70.62% | +10.85 pp |
| 2022 | 2022-12-31 | 59.77% | −14.64 pp |
| 2021 | 2021-12-31 | 74.41% | +1.36 pp |
| 2020 | 2020-12-31 | 73.05% | +2.56 pp |
| 2019 | 2019-12-31 | 70.48% | +3.77 pp |
| 2018 | 2018-12-31 | 66.72% | +3.14 pp |
| 2017 | 2017-12-31 | 63.58% | −4.35 pp |
| 2016 | 2016-12-31 | 67.93% | +14.10 pp |
| 2015 | 2015-12-31 | 53.82% | +5.58 pp |
| 2014 | 2014-12-31 | 48.24% | +27.15 pp |
| 2013 | 2013-12-31 | 21.10% | −55.13 pp |
| 2012 | 2012-12-31 | 76.22% | +8.82 pp |
| 2011 | 2011-12-31 | 67.40% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 73.18% | +2.32 pp |
| Q1 2026 | 2026-03-31 | 69.16% | −1.97 pp |
| Q4 2025 | 2025-12-31 | 73.68% | +5.33 pp |
| Q3 2025 | 2025-09-30 | 70.28% | +9.26 pp |
| Q2 2025 | 2025-06-30 | 70.85% | −2.69 pp |
| Q1 2025 | 2025-03-31 | 71.12% | −5.34 pp |
| Q4 2024 | 2024-12-31 | 68.35% | −74.80 pp |
| Q3 2024 | 2024-09-30 | 61.02% | −2.61 pp |
| Q2 2024 | 2024-06-30 | 73.55% | +9.66 pp |
| Q1 2024 | 2024-03-31 | 76.46% | +18.73 pp |
| Q4 2023 | 2023-12-31 | 143.15% | +81.84 pp |
| Q3 2023 | 2023-09-30 | 63.64% | +19.04 pp |
| Q2 2023 | 2023-06-30 | 63.89% | +5.68 pp |
| Q1 2023 | 2023-03-31 | 57.73% | −16.06 pp |
| Q4 2022 | 2022-12-31 | 61.31% | −9.73 pp |
| Q3 2022 | 2022-09-30 | 44.60% | −30.17 pp |
| Q2 2022 | 2022-06-30 | 58.21% | −19.25 pp |
| Q1 2022 | 2022-03-31 | 73.79% | −0.25 pp |
| Q4 2021 | 2021-12-31 | 71.04% | −7.82 pp |
| Q3 2021 | 2021-09-30 | 74.77% | +2.17 pp |
| Q2 2021 | 2021-06-30 | 77.46% | +10.64 pp |
| Q1 2021 | 2021-03-31 | 74.04% | +1.43 pp |
| Q4 2020 | 2020-12-31 | 78.86% | +7.05 pp |
| Q3 2020 | 2020-09-30 | 72.59% | +0.42 pp |
| Q2 2020 | 2020-06-30 | 66.82% | −3.75 pp |
| Q1 2020 | 2020-03-31 | 72.61% | +6.10 pp |
| Q4 2019 | 2019-12-31 | 71.81% | +15.36 pp |
| Q3 2019 | 2019-09-30 | 72.17% | +7.91 pp |
| Q2 2019 | 2019-06-30 | 70.57% | −5.11 pp |
| Q1 2019 | 2019-03-31 | 66.51% | −9.21 pp |
| Q4 2018 | 2018-12-31 | 56.45% | −4.51 pp |
| Q3 2018 | 2018-09-30 | 64.26% | −2.65 pp |
| Q2 2018 | 2018-06-30 | 75.68% | +7.14 pp |
| Q1 2018 | 2018-03-31 | 75.72% | +16.01 pp |
| Q4 2017 | 2017-12-31 | 60.96% | −40.45 pp |
| Q3 2017 | 2017-09-30 | 66.91% | +6.87 pp |
| Q2 2017 | 2017-06-30 | 68.54% | +7.83 pp |
| Q1 2017 | 2017-03-31 | 59.71% | +4.98 pp |
| Q4 2016 | 2016-12-31 | 101.40% | +47.05 pp |
| Q3 2016 | 2016-09-30 | 60.03% | +7.58 pp |
| Q2 2016 | 2016-06-30 | 60.71% | +8.99 pp |
| Q1 2016 | 2016-03-31 | 54.73% | −3.16 pp |
| Q4 2015 | 2015-12-31 | 54.35% | −7.95 pp |
| Q3 2015 | 2015-09-30 | 52.45% | −6.60 pp |
| Q2 2015 | 2015-06-30 | 51.72% | +16.73 pp |
| Q1 2015 | 2015-03-31 | 57.89% | +20.27 pp |
| Q4 2014 | 2014-12-31 | 62.31% | +57.61 pp |
| Q3 2014 | 2014-09-30 | 59.06% | +29.53 pp |
| Q2 2014 | 2014-06-30 | 34.99% | +3.45 pp |
| Q1 2014 | 2014-03-31 | 37.62% | +5.90 pp |
| Q4 2013 | 2013-12-31 | 4.70% | −66.68 pp |
| Q3 2013 | 2013-09-30 | 29.53% | −47.04 pp |
| Q2 2013 | 2013-06-30 | 31.54% | −189.28 pp |
| Q1 2013 | 2013-03-31 | 31.73% | +53.12 pp |
| Q4 2012 | 2012-12-31 | 71.37% | — |
| Q3 2012 | 2012-09-30 | 76.57% | — |
| Q2 2012 | 2012-06-30 | 220.82% | — |
| Q1 2012 | 2012-03-31 | −21.39% | — |
Over the last five reported fiscal years, Cytosorbents's gross margin decreased from 73.05% to 71.48%, a change of −1.57 percentage points. The latest reported quarter, Q2 2026, shows 73.18%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cytosorbents filings at SEC.gov ↗